Updating a clinical prediction model for identifying monogenic diabetes to include both clinical features and biomarkers

<p dir="ltr">Objective </p><p dir="ltr">Selecting appropriate individuals for monogenic diabetes genetic testing is challenging. We aimed to develop a new probability calculator, integrating clinical features and biomarkers, to aid identification of monogenic diabetes. </p><p dir="ltr">Research Design and Methods </p><p dir="ltr">We developed two prediction models (for early-insulin-treated, proxy for type 1 diabetes; and not-early-insulin-treated patients, proxy for type 2 diabetes) using a Bayesian recalibration mixture model approach. We used case-control data (monogenic diabetes=594, non-monogenic diabetes diabetes=597) for initial model development (clinical features only) and recalibrated to population-data (UNITED study, n=1,299) including biomarkers (C-peptide and islet-autoantibodies). We externally validated the calculator in an independent population-based cohort (n=1,025). </p><p dir="ltr">Results</p><p dir="ltr">For early-insulin-treated individuals, the model incorporating biomarkers improved discrimination over using clinical features only (ROCAUC 0.98 [95%CrI 0.95–0.98] vs. 0.80 [95%CrI 0.71–0.82], p<0.001) or biomarkers alone (ROC AUC 0.96 [95% CI 0.95–0.97]). For not-early-insulin-treated participants, the calculator showed good discrimination (ROCAUC: 0.86 [95%CrI 0.85–0.88]). Both models calibrated well and showed good discrimination in external validation (0.98 and 0.92 for early- and not-early-insulin-treated individuals, respectively). Using a ≥5% probability threshold to guide testing results in positive test rates for monogenic diabetes of 16–19%. </p><p dir="ltr">Conclusions</p><p dir="ltr">We developed an updated monogenic diabetes probability calculator that integrates both clinical features and biomarkers, providing greater discrimination than using clinical features or biomarkers alone and providing appropriate measures for selecting individuals for monogenic diabetes diagnostic testing. This is now available as an online calculator and has immediate clinical utility for White European individuals diagnosed with diabetes ≤35 years. </p><p><br></p>

Authors

Publication Details

Published
2025-10-14
DOI
https://doi.org/10.2337/figshare.30138886.v1
Primary Topic
Machine Learning in Healthcare
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Updating a clinical prediction model for identifying monogenic diabetes to include both clinical features and biomarkers

Kevin Colclough, Katherine Young, Pedro Cardoso, Shivani Misra et al.
Machine Learning in Healthcare
article

Updating a clinical prediction model for identifying monogenic diabetes to include both clinical features and biomarkers

Kevin Colclough, Katherine Young, Pedro Cardoso, Shivani Misra, Angus G. Jones, Trevelyan J. McKinley, Andrew Tym Hattersley, Beverley M. Shields, Julieanne Knupp, Ewan R. Pearson, Kashyap Patel, Sophie Jones, Timothy J. McDonald
article en

Abstract

<p dir="ltr">Objective </p><p dir="ltr">Selecting appropriate individuals for monogenic diabetes genetic testing is challenging. We aimed to develop a new probability calculator, integrating clinical features and biomarkers, to aid identification of monogenic diabetes. </p><p dir="ltr">Research Design and Methods </p><p dir="ltr">We developed two prediction models (for early-insulin-treated, proxy for type 1 diabetes; and not-early-insulin-treated patients, proxy for type 2 diabetes) using a Bayesian recalibration mixture model approach. We used case-control data (monogenic diabetes=594, non-monogenic diabetes diabetes=597) for initial model development (clinical features only) and recalibrated to population-data (UNITED study, n=1,299) including biomarkers (C-peptide and islet-autoantibodies). We externally validated the calculator in an independent population-based cohort (n=1,025). </p><p dir="ltr">Results</p><p dir="ltr">For early-insulin-treated individuals, the model incorporating biomarkers improved discrimination over using clinical features only (ROCAUC 0.98 [95%CrI 0.95–0.98] vs. 0.80 [95%CrI 0.71–0.82], p<0.001) or biomarkers alone (ROC AUC 0.96 [95% CI 0.95–0.97]). For not-early-insulin-treated participants, the calculator showed good discrimination (ROCAUC: 0.86 [95%CrI 0.85–0.88]). Both models calibrated well and showed good discrimination in external validation (0.98 and 0.92 for early- and not-early-insulin-treated individuals, respectively). Using a ≥5% probability threshold to guide testing results in positive test rates for monogenic diabetes of 16–19%. </p><p dir="ltr">Conclusions</p><p dir="ltr">We developed an updated monogenic diabetes probability calculator that integrates both clinical features and biomarkers, providing greater discrimination than using clinical features or biomarkers alone and providing appropriate measures for selecting individuals for monogenic diabetes diagnostic testing. This is now available as an online calculator and has immediate clinical utility for White European individuals diagnosed with diabetes ≤35 years. </p><p><br></p>

Openalex Percentile: Top 85%
Machine Learning in Healthcare
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.